Corbion N.V. (CRBN) Earnings Call Transcripts
Corbion N.V.'s Latest Earnings Call - Q1 FY2026
In Q1 2026, Corbion N.V. reported group sales of nearly EUR 294 million and adjusted EBITDA of EUR 37.8 million, reflecting a decline from the previous year but in line with management's expectations. The company expects a clear acceleration in both volume and earnings as the year progresses, driven by strong demand in Functional Ingredients & Solutions and Health & Nutrition. Management reaffirmed its full-year guidance, targeting 3% to 6% organic sales growth and an adjusted EBITDA margin of around 17%.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | EUR 294 million (miss) |
| Adjusted EBITDA | EUR 37.8 million (miss) |
| Adjusted EBITDA Margin | 12.9% (miss) |
| Free Cash Flow | EUR -15.7 million (inline) |
| Organic Sales Growth Guidance | 3% to 6% (inline) |
| Adjusted EBITDA Margin Guidance | around 17% (inline) |
Guidance from management
Management reaffirmed its full-year guidance, targeting 3% to 6% organic sales growth and an adjusted EBITDA margin of around 17%. They expect a clear improvement in performance as the year progresses, particularly in the second half.
What management said
No, it includes some small adjusted items related to 2 different elements. One is the divestment process of PLA, as you can imagine. And the other one, which is good news, which you will not see basically in our numbers, but only in -- sorry, H1, is that we had a positive tax outcome in a discussion with the Spanish authorities, which would have a positive impact of around EUR 5 million in terms of tax this year, and...
No, it's a pretty good -- we have very good visibility on Q2, very good, and it's really a very strong start of Q2 there. So I'm feeling really good, feeling really confident what we see in both divisions actually already in April.
What analysts pressed on
Analysts expressed concerns about the softness in the North American market, particularly in bakery and meat categories. There were also questions regarding the impact of inflation on pricing dynamics and the potential for further volume growth in Health & Nutrition.
Main topics on the call
- Sales Performance and Momentum — Corbion reported Q1 sales of nearly EUR 294 million, with stable sales of EUR 236 million in Functional Ingredients & Solutions. Management noted, "April trading confirms that momentum is building," indicating expectatio...
- Health & Nutrition Recovery — Sales in Health & Nutrition were nearly EUR 58 million, reflecting phasing effects. Management stated, "We expect a normalization of sales and volume growth from the second quarter onwards," signaling a positive outlook ...
- Cost Reduction Initiatives — Corbion is implementing a focused cost reduction program, with management anticipating an increase of around EUR 5 million in savings starting from Q2. This is expected to support margin improvement as the year progresse...
- Market Dynamics and Pricing — Management acknowledged ongoing inflationary pressures and the impact of geopolitical tensions on costs. They are actively managing pricing mechanisms to mitigate these effects, indicating a cautious but proactive approa...
Read the full Corbion N.V. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Corbion N.V.
Corbion N.V. (CRBN) is a publicly listed company in the Chemicals industry, within the Materials sector. It trades on ENXTAM and is based in NL. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 30 calls on record spanning March 9, 2020 to July 31, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 30 Corbion N.V. earnings call transcripts on record, spanning March 9, 2020 to July 31, 2026. Based on this history, Corbion N.V. reports quarterly. The most recent call on file is dated July 31, 2026. The full list is below — each row opens the complete, free-to-read transcript.